BioTech
Biotech and life-sciences VCs — therapeutics, diagnostics, computational biology, drug discovery, synthetic biology, and biomanufacturing. Stage-aware filtering for seed-to-Series C founders.
16
20
0
Top VCs investing in BioTech
View all VCs →Founders Fund
San Francisco, CA
Khosla Ventures
Menlo Park, CA
SBI Investment
Tokyo, Japan
ANRI
Tokyo, Japan
UTEC
Tokyo, Japan
Lux Capital
New York, NY
Andreessen Horowitz Bio Fund
Menlo Park, CA
OrbiMed
New York, NY
ARCH Venture Partners
Chicago, IL
Polaris Partners
Boston, MA
Atlas Venture
Cambridge, MA
F-Prime Capital
Boston, MA
Prime Movers Lab
Jackson, WY
Fifty Years
San Francisco, CA
DCVC (Data Collective)
San Francisco, CA
GV (Andreessen Bio separate)
Menlo Park, CA
Recent investment signals
Boston biotech sector remains strong but undersized relative to AI mega-rounds; over 50% of Boston's largest funded startups in 2024 are biotech/healthcare focused.
Source: Boston Startup Fundraising Looks Strong Only By Pre-AI ParametersClearNote Health raised $52M in Series D for early cancer detection and monitoring tests.
Source: The Week’s 10 Biggest Funding Rounds: Anthropic Dominates In An Otherwise Slower Week For MegaroundsOctant secured a partnership with Bristol Myers Squibb, a major pharmaceutical company, validating its technology and market relevance.
Source: Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson SonsiniOctant raised $80 million in Series B funding, indicating strong investor confidence in the company's biotech capabilities and commercial potential.
Source: Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson SonsiniAndreessen Horowitz is increasing its focus and investment activity in the biotech sector, signaling confidence in the space's long-term potential.
Source: Andreessen Horowitz Is Digging Deeper Into Biotech - BuzzFeed NewsUSV lists bio as one of four main investment domains for analyst focus and portfolio development.
Source: USV Analyst Program 2026Orbis Medicines raised EUR 90 million in Series A funding to develop a pipeline of oral macrocycle therapeutics, indicating investor confidence in the company's drug development approach.
Source: Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles - Business WireBiology is becoming more engineerable through AI and biotech tooling, representing a Version One moment where the intersection of deep science and AI creates a significant investable opportunity.
Source: We’re Bio-BullishLaunching a special investment vehicle led by a former bio founder to back earliest-stage biotinkerers working through scientific and technical risk.
Source: We’re Bio-BullishIdeal biotech founders are deeply technical but not traditionally trained in biology, bring outsider perspectives enabled by AI, collaborate with world-class scientists, and focus on commercializing existing research through creative regulatory paths.
Source: We’re Bio-BullishFrequently asked questions
Which VCs are most active in BioTech?
VCWorld ranks VCs by the volume of BioTech-related investment signals and articles. Top of the list = funds actively publishing theses, blogs, and announcing investments in this sector.
How can I narrow down BioTech VCs further?
This hub shows VCs whose focusSectors includes BioTech. Combine it with region hubs (e.g. /regions/us) or stage hubs (e.g. /stages/seriesA) for a tighter shortlist.
What is an investment signal?
Structured data extracted by AI from each VC's official blog and partner-authored articles. We classify signals into thesis, investment, trend, or opinion, each tagged with a confidence score (0-100%).
Where can I see the latest BioTech trends?
The "Signals" section above and the /trends page surface the most recent BioTech signals from the past 30 days, sorted by recency and confidence.